



OMED[®] 2020

ENVISION A PATH TO SUCCESS

OCT 15-18 ———  ——— VIRTUAL



Management of Rapid Atrial Fibrillation: A Clean Sweep of Focused Care Points

Lamont Mitchell, DO

Attending Physician Emergency Medicine

Board Certified Emergency Medicine

Board Certified Family Medicine

Disclosures

- None to report

Key Points of This Lecture

- Recognition of atrial fibrillation
- Medical decision crossroads in managing rapid atrial fibrillation
- Review treatment options for rapid atrial fibrillation

Recognition


Disorganized atrial electrical activity and contraction



- **IRREGULARLY IRREGULAR RHYTHM**
- **NO DISCERNIBLE P WAVES**
- Variable ventricular rate
- **QRS complexes usually < 120ms (3 little boxes)** unless pre-existing bundle branch block, accessory pathway, or rate related aberrant conduction.
- **FIBRILLATORY WAVES** may be present and can be either fine (amplitude < 0.5mm) or coarse (amplitude >0.5mm)
- **Fibrillatory waves may mimic P waves leading to misdiagnosis**

Recognition

Rapid disorganized atrial electrical activity and contraction



I MUST BREAK YOU

Treatment Toolbag

Cardioversion

Beta blockers


- Metoprolol
- Esmolol

Calcium channel blockers

Digoxin

Amiodarone

RAPID ATRIAL FIBRILLATION TREATMENT ALGORITHM





Unstable

- Ischemic chest pain
- SBP <90
- Acute pulmonary edema
- Altered mental status

Unstable - Synchronized cardioversion

Dosing

- A-fib start at 200 J
- A-flutter start at 50 J

Do

- Sedate

Don't

- Not sedate
- Defibrillate





Stable

- No ischemic chest pain
- SBP >90
- No acute pulmonary edema
- No altered mental status



Beta blockers

- Metoprolol
- Esmolol

Calcium channel blockers

Digoxin

Amiodarone

Calcium channel blockers

Dosing


- Diltiazem
 - Bolus .25 mg/kg over 2 min
 - Repeat bolus .35 mg/kg after 15 min
 - Infusion 5-15 mg/hr or
 - PO 60 mg QID

Do

- Bronchospasm
 - Asthma
 - COPD

Don't

- Decompensated heart failure
- Preexcitation
- Hypotension (SBP <90)



Beta blockers

Dosing

- Metoprolol
 - Bolus 2.5 - 5 mg IV over 2 min q5min up to 3 doses
 - If responds, load PO 25-50mg
 - (tartrate BID)
 - (~~succinate QD~~)

Dosing

- Esmolol
 - Bolus .5 mg/kg, then 50 mcg/kg/min
 - Rebolus in increments

Do

- Exercise
- Myocardial infarction
- Thyrotoxicosis

Do


- Higher safety profile since duration is only 10 minutes

Don't

- Decompensated heart failure
- COPD
- Asthma
- Hypotension (SBP <90)

Don't

- Not reference dosing




Digoxin

Dosing

- Load 0.25mg IV q2hr
 - up to 1.5mg
- then 0.125-0.25mg PO or IV QD

Do/Don't

- Consider initially: therapy for patients with LV dysfunction who:
 - Decompensated CHF
 - Improve CHF symptoms
 - Hypotension (SBP<90 or relatively low)
- Consider as 2nd line agent
- 6-8 hour onset



Amiodarone

Dosing

- Rate control
 - 300mg IV x1, then
 - 10-50 mg/hr IV x 24 hours
- Rhythm control
- Cardioversion


Do/Don't

- Consider for:
 - Decompensated CHF
 - Preexcitation
- 2nd-line agent for chronic rate control



Clinical Scenarios

Case Scenario 1



Chief complaint: 52 yo male with palpitations x 3 days

PMHx: HTN

Meds: Multivitamin

Vitals: Temp: 98.6 F

Blood pressure: 148/90 mmHg

HR: 120-140 bpm

RR: 12 per min

Pulse ox: 100% RA



Case Scenario 1



1. A-fib with RVR?
2. Stable or unstable?
3. Symptoms?
4. At HR goal?
5. Treatment options?

Chief complaint: palpitations x 3 days

PMHx: HTN

Meds: lisinopril


Vitals: Temp: 98.6 F

Blood pressure: 148/90 mmHg

HR: 120-140 bpm

RR: 12 per min

Pulse ox: 100% RA



Case Scenario 1

Chief complaint: palpitations x 3 days

PMHx: HTN

Meds: lisinopril

Vitals: Temp: 98.6 F

Blood pressure: 148/90 mmHg

HR: 120-140 bpm

RR: 12 per min


Pulse ox: 100% RA



Treatment?

- Cardioversion?
- IV Rate Control?
- PO Rate Control?
- Do Nothing?

NEXT CASE




Case Scenario 2

Chief complaint: 64 F presents with exercise intolerance, dyspnea on exertion and peripheral edema for 6 days

PMHx: CHF, HTN, MI

Meds: lisinopril

Vitals: Temp: 98.6 F
Blood pressure: 148/90 mmHg
HR: 160-180 bpm
RR: 12 per min
Pulse ox: 100% RA



Case Scenario 2


A junior resident is on the case.

Furosemide 60mg IV was given. Patient urinated 1000cc urine.

A bolus of diltiazem 25mg was given.

The patient's blood pressure dropped to 90/54.

The resident is now asking for you to save them from further evil.



Case Scenario 2



1. A-fib with RVR
2. Stable or unstable
3. Symptoms?
4. At HR goal?
5. Treatment options?

Chief complaint: 64 F presents with exercise intolerance, dyspnea on exertion and peripheral edema for 6 days

PMHx: CHF, HTN, MI

Meds: lisinopril

Vitals: Temp: 98.6 F


Blood pressure: 148/90 mmHg

HR: 160-180 bpm

RR: 12 per min

Pulse ox: 100% RA

NEXT CASE



Case Scenario 3

Chief complaint: 54 M with productive cough, fever, weakness for 5 days

PMHx: COPD, Afib, HTN

Meds: lisinopril, apixaban


Vitals: Temp: 101.4 F (oral)

Blood pressure: 94/48 mmHg
(MAP 63)

HR: 120-140 bpm


RR: 22 per min

Pulse ox: 92% RA





Case Scenario 3



1. A-fib with RVR?
2. Stable or unstable?
3. Symptoms?
4. At HR goal?
5. Treatment options?

Chief complaint: 54 M with productive cough, fever, weakness for 5 days

PMHx: COPD, Afib, HTN

Meds: lisinopril, apixaban

Vitals: Temp: 101.4 F

Blood pressure: 94/48 mmHg (MAP 63)

HR: 120-140 bpm

RR: 22 per min

Pulse ox: 92% RA



Case Scenario 3



Treatment Options

Cardioversion
IV Rate Control
PO Rate Control
Do Nothing

Treat the Sepsis

Chief complaint: 54 M with productive cough, fever, weakness for 5 days

PMHx: COPD, Afib, HTN

Meds: lisinopril, apixaban

Vitals: Temp: 101.4 F

Blood pressure: 94/48 mmHg (MAP 63)

HR: 120-140 bpm

RR: 22 per min


Pulse ox: 92% RA

References

- Efremidis M, Pappas L, Sideris A, Filippatos G. Management of atrial fibrillation in patients with heart failure. *J Cardiac Fail.* 2008; 14: 232-237.
- Stevenson WG, Stevenson LW. Atrial fibrillation and heart failure: five more years. *N Engl J Med.* 2004; 351: 2437.
- Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. *N Engl J Med.* 2008; 358: 2667-2677.
- Owan T, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. *N Engl J Med.* 2006; 355: 251-259.
- Hunt SA; American College of Cardiology; American Heart Association Task Force on Practice Guidelines. ACC/AHA 2005 guideline update for the diagnosis management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2005; 46: e1-e82.
- Neuberger HR, Mewis C, van Veldhuisen DJ, Schotten U, van Gelder IC, Allessie MA, Böhm M. Management of atrial fibrillation in patients with heart failure. *Eur Heart J.* 2007; 28: 2568-2577.
- Fromm C, Suau SJ, Cohen V, et al. Diltiazem vs. metoprolol in the management of atrial fibrillation or flutter with rapid ventricular rate in the emergency department. *J Emerg Med* 2015;49:175-82.
- January CT, Wann LS, Alpert JS, et al. 2014 AHA/ ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. *Circulation* 2014;130:2071-104.
- Stiell IG, Macle L. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: management of recent-onset atrial fibrillation and flutter in the emergency department. *Can J Cardiol* 2011;27:38-46.
- Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. *J Am Coll Cardiol* 2001;38:1231-66.
- Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Cardiothorac Surg* 2016;70:e1-88.
- Macle L, Cairns J, Leblanc K, et al. 2016 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. *Can J Cardiol* 2016;32:1170-85.

LAMONT MITCHELL, DO
LLMITCHELLDO@GMAIL.COM

Thank You



The good ol' days



Patient presents with ear pain.



OMED[®] 2020

ENVISION A PATH TO SUCCESS

OCT 15-18 ———  ——— VIRTUAL